肠道菌群失调在慢性肝病发病中的作用研究进展

doi:10.3969/j.issn.1672-5069.2014.01.034

Abstract

Abstract: Intestinal flora is an important part of the intestinal barrier. Under healthy condition,a normal balance of intestinal flora is maintained, however, under pathological circumstances a number of factors can change the balance and result in dysbacteriosis. In turn dysbacteriosis promotes the progress and exacerbation of chronic liver diseases. Administration of probiotics can improve the balance of intestinal flora and help the recovery of chronic liver disease.

Key words: Cirrhosis, Non-alcoholic fatty liver disease, Alcoholic liver disease, Dysbacteriosis

Zhao Xin, Zhao Caiyan. Progress in dysbacteriosis in chronic liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(1): 106-109.

References

[1] 贾辅忠. 肝病与肠道微生态环境. 中国实用内科杂志,2006, 26（13）：971-974.
[2] 姜秀菊. 肠道菌群失调与多脏器功能衰竭. 中国微生态学杂志, 2008,20（4）：424.
[3] Woo PC,Fung AM,Lau SK,et al. Identification by 16S rRNA gene sequencing of Lactobacillus salivarius bacteremic cholecystitis. J Clin Microbiol,2002,40（1）：265-257.
[4] 沈镭,陆伦根. 肠道微生态与肝硬化. 肝脏,2006,11（4）：278-280.
[5] Bliss SK,Bliss SP,Beiting DP,et al. IL-10 regulates movement of intestinally derived CD4+ T cells to the liver. J Immunol, 2007,178（12）：7974-7983.
[6] Gao B,Jeong WI,Tian Z,Liver：An organ with predominant innate immunity. Hepatology,2008,47（2）：729-736.
[7] Li L,Wu Z,Ma W,et al. Changes in intestinal microflora in patients with chronic severe hepatitis. Chin Med J,2001,114（8）：869-872.
[8] 吴仲文. 肠道屏障与肠道微生态. 中国危重病急救医学, 2004,16（12）：768-770.
[9] 鞠宝玲,唐小云,张红军,等. 菌群失调小鼠全身及肠道局部免疫功能的实验研究. 热带医学杂志,2008,8（5）：445-446.
[10] 杨洁,聂青和. 肝衰竭与肠道屏障功能障碍. 实用肝脏病杂志, 2010,13（1）：66-69.
[11] 朱宁川,陈岩. 肝病肠道菌群失调与肠源性内毒素血症. 中国微生态学杂志,2004,16（1）：61.
[12] Dagvadorj J,Tumurkhuu G,Naiki Y,et al. Endotoxin-induced lung injury in alpha-galactosylceramide-sensitized mice is caused by failure of interleukin-4 production in lung natural killer T cells. Clin Exp Immunol,2010,162（1）：169-177.
[13] 吴卫锋,戴玮玮. 细胞因子在慢性肝衰竭合并全身炎症反应综合征病例中的意义. 中国生化药物杂志,2009,30（1）：52-53.
[14] 江丰,吴蓉,吴小翎. 口服肠道益生菌制剂对肝硬化患者血浆脂多糖连接蛋白水平的影响及其临床意义. 实用肝脏病杂志,2006, 9（4）：246-248.
[15] Day CP,James OF. Steatohepatitis：a tale of two “hits”Gastroenterology,1998,114（4）：842-845.
[16] Farrell GC. Signalling links in the liver：knitting SOCS with fat and inflammation. J Hepatol,2005,43（1）：193-196.
[17] Vijay-Kumar M,Aitken JD,Carvalho FA,et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science,2010,328（5975）：228-231.
[18] Rabot S,Membrez M,Bruneau A,et al.Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism. Faseb J,2010,24（12）：4948-4959.
[19] Abu-Shanab A,Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol, 2010,7（12）：691-701.
[20] Musso G,Gambino R,Cassader M. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition：mechanisms and implications for metabolic disorders. Curr Opin Lipidol,2010, 21（1）：76-83.
[21] Musso G,Gambino R,Cassader M. Obesity,diabetes,and gut microbiota：the hygiene hypothesis expanded? Diabetes Care,2010,33（10）：2277-2284.
[22] Szabo G,Bala S,Petrasek J,et al. Gut-liver axis and sensing microbes. Dig Dis,2010,28（6）：737-744.
[23] Diamant M,Blaak EE,de Vos WM. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes? Obes Rev,2011,2（4）：272-281.
[24] Iacono A,Raso GM,Canani RB,et al. Probiotics as an emerging therapeutic strategy to treat NAFLD：focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）： 699-711.
[25] Sajjad A,Mottershead M,Syn WK,et al. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther,2005,22（4）：291-299.
[26] Fan JG,Xu ZJ,Wang GL. Effect of lactulose on establishment of a rat non-alcoholic steatohepatitis model. World J Gastroenterol, 2005,11（32）：5053-5056.
[27] Wu WC,Zhao W,Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol,2008,14（2）：313-317.
[28] Iacono A,Raso GM,Canani RB,et al. Probiotics as an emerging therapeutic strategy to treat NAFLD：focus on molecular and biochemical mechanisms. J Nutr Biochem,2011,22（8）：699-711.
[29] Cesaro C,Tiso A,Del Prete A,et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis,2011,43（6）：431-438.
[30] Rao RK,Seth A,Sheth P. Recent advances in alcoholic liver disease：Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol,2004,286（6）：G881-884.
[31] Szabo G,Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol,2010,16（11）：1321-1329.
[32] Mutlu E,Keshavarzian A,Engen P,et al. Intestinal dysbiosis： a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res,2009,33（10）：1836-1846.
[33] Bhonchal S,Nain CK,Taneja N,et al.Modification of small bowel microflora in chronic alcoholics with alcoholic liver disease. Trop Gastroenterol,2007,28（2）：64-66.
[34] Forsyth CB,Farhadi A,Jakate SM,et al. Lactobacillus GG treatment ameliorates alcohol-induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol,2009,43（2）：163-172.
[35] Martin FP,Sprenger N,Yap IK,et al. Panorganismal gut microbiome-host metabolic crosstalk. J Proteome Res,2009,8（4）： 2090-2105.

Progress in dysbacteriosis in chronic liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Zhu Yage, Liu Jinfeng.. Therapeutic efficacy of adenosine methionine and glycyrrhizin combination in treatment of patients with alcoholic cirrhosis and its effect on serum BGP levels [J]. Journal of Practical Hepatology, 2019, 22(6): 872-875.
[4]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[5]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[6]	Liu Li, Yang Lie, Chen Haiyang, et al.. Changes of hemodynamics after splenectomy combined with pericardial devascularization in patients with cirrhotic portal hypertention complicated by splenic artery steal syndrome [J]. Journal of Practical Hepatology, 2019, 22(6): 884-887.
[7]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[8]	Zhang Xu Lei, Yang Qingyu, Han Qiuyu, et al. Short-term efficacy of herbal medicine in treatment of patients with nonalcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2019, 22(5): 660-663.
[9]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[10]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[11]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[12]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[13]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[14]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[15]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.